FDA approves combination of nivolumab and ipilimumab as treatment for hepatocellular carcinoma in patients who have been previously treated with sorafenib

Approval was based on results from phase I/II CheckMate-040 trial in which combination showed overall response rate of 33% (8% complete response) and duration of responses ranged from 4.6 to 30.5 months, with 88% lasting at least six months.


Biospace Inc.